A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb5871 in Patients with IgG4-Related Disease (INDIGO)
Phase of Trial: Phase III
Latest Information Update: 24 Nov 2018
At a glance
- Drugs Obexelimab (Primary)
- Indications Immunological disorders
- Focus Registrational; Therapeutic Use
- Acronyms INDIGO
- Sponsors Xencor
- 05 Nov 2018 According to a Xencor media release, company plans to initiate this trial by Early 2019.
- 05 Oct 2018 According to a Xencor media release, this study is expected to start by year end.
- 27 Feb 2018 According to a Xencor media release, Engagement with the European Medicines Agency to discuss a path forward for Phase 3 development in IgG4-RD expected in early 2018.